The Phase I trial of anti-CD22 CAR T cells, sponsored by the National Cancer Institute, targets pediatric and young adult patients with recurrent or refractory CD22-expressing B cell malignancies. Given the high unmet medical need in this demographic, particularly for those who have failed standard therapies, this asset has significant commercial potential. The success of this trial could position the NCI as a leader in CAR T cell therapy for pediatric cancers, potentially attracting partnerships with larger biopharma companies for further development and commercialization. The competitive landscape includes existing CD19-targeted CAR therapies, but the introduction of CD22 as a target may mitigate the risk of antigen escape seen with CD19 therapies. Diligence should focus on the trial's safety profile, efficacy data, and potential for regulatory approval pathways.